摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1-dimethylethyl 6-(3,4-dichlorophenyl)-1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate

中文名称
——
中文别名
——
英文名称
1,1-dimethylethyl 6-(3,4-dichlorophenyl)-1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate
英文别名
1,1-dimethylethyl (1R,6S/1S,6R)-6-(3,4-dichlorophenyl)-1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate;tert-butyl (1S,6R)-6-(3,4-dichlorophenyl)-1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate
1,1-dimethylethyl 6-(3,4-dichlorophenyl)-1-formyl-3-azabicyclo[4.1.0]heptane-3-carboxylate化学式
CAS
——
化学式
C18H21Cl2NO3
mdl
——
分子量
370.276
InChiKey
AHYKSCQGUGLUSQ-ROUUACIJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] AZABICYCLO [4.1.0] HEPTANE DERIVATIVES AND THEIR USE AS MONOAMINE REUPTAKE INHIBITORS<br/>[FR] DÉRIVÉS DE L'AZABICYCLO [4.1.0] HEPTANE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RECAPTURE DE MONOAMINES
    申请人:GLAXO GROUP LTD
    公开号:WO2010130672A1
    公开(公告)日:2010-11-18
    The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors, wherein R4 is a carbonyl containing group.
    本发明涉及公式(I)的化合物,其制备方法,用于这些制备方法的中间体,包含它们的制药组合物以及它们在治疗中的应用,作为血清素(5-HT),多巴胺(DA)和去甲肾上腺素(NE)的再摄取抑制剂,其中R4是含有羰基的基团。
  • [EN] TRICYCLIC AZABICYCLO [4.1.0] HEPTANE DERIVATIVES AS INHIBITORS OF SEROTONIN, DOPAMINE AND NOREPINEPHRINE RE-UPTAKE<br/>[FR] DÉRIVÉS D'AZABICYCLO [4.1.0] HEPTANE TRICYCLIQUES UTILISÉS COMME INHIBITEURS DU RECAPTAGE DE LA SÉROTONINE, DE LA DOPAMINE ET DE LA NORÉPINÉPHRINE
    申请人:GLAXO GROUP LTD
    公开号:WO2010146025A1
    公开(公告)日:2010-12-23
    The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.
    该发明涉及公式(I)的化合物,其制备过程,用于这些过程的中间体,包含它们的制药组合物以及它们在治疗中的应用,作为血清素(5-HT)、多巴胺(DA)和去甲肾上腺素(NE)的再摄取抑制剂。
  • 6-(3,4-Dichlorophenyl)-1-[(Methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A New Potent and Selective Triple Reuptake Inhibitor
    作者:Fabrizio Micheli、Paolo Cavanni、Daniele Andreotti、Roberto Arban、Roberto Benedetti、Barbara Bertani、Michela Bettati、Letizia Bettelini、Giorgio Bonanomi、Simone Braggio、Renzo Carletti、Anna Checchia、Mauro Corsi、Elettra Fazzolari、Stefano Fontana、Carla Marchioro、Emilio Merlo-Pich、Michele Negri、Beatrice Oliosi、Emiliangelo Ratti、Kevin D. Read、Maja Roscic、Ilaria Sartori、Simone Spada、Giovanna Tedesco、Luca Tarsi、Silvia Terreni、Filippo Visentini、Alessandro Zocchi、Laura Zonzini、Romano Di Fabio
    DOI:10.1021/jm100481d
    日期:2010.7.8
    A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported. Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics. Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT. In vivo microdialysis experiments in different animal models and receptor occupancy studies in rat confirmed that derivative 17 showed an appropriate profile to further progression of the compound.
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
    申请人:GLAXO GROUP LTD
    公开号:WO2009109608A1
    公开(公告)日:2009-09-11
    The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.
    该发明涉及式(I)的化合物,其制备方法,用于这些方法的中间体,含有它们的药物组合物以及它们在治疗中的应用,作为血清素(5-HT)、多巴胺(DA)和去甲肾上腺素(NE)的再摄取抑制剂。
  • 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: Further insights into a class of triple re-uptake inhibitors
    作者:Fabrizio Micheli、Paolo Cavanni、Michela Bettati、Giorgio Bonanomi、Romano Di Fabio、Elettra Fazzolari、Carla Marchioro、Maja Roscic、Luca Tarsi、Filippo Visentini、Laura Zonzini、Angela Worby
    DOI:10.1016/j.bmc.2011.04.032
    日期:2011.6
    Further exploration around the recently disclosed potent triple re-uptake inhibitor 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane led to the identification of a new series of potent triple re-uptake inhibitors endowed with good developability characteristics. The insertion of a further aryl moiety into the template allowed the ‘titration’ of the SERT/NET/DAT ratio leading
    围绕最近公开的有效的三重再摄取抑制剂6-(3,4-二氯苯基)-1-[((甲氧基)甲基] -3-氮杂双环[4.1.0]庚烷)的进一步探索导致鉴定出一系列新的有效三重再摄取抑制剂具有良好的可显影性。在模板中插入另外的芳基部分,可以“滴定” SERT / NET / DAT比率,从而确定了这一重要领域中的其他工具。
查看更多